PL208588B1 - Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa - Google Patents
Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusaInfo
- Publication number
- PL208588B1 PL208588B1 PL373337A PL37333703A PL208588B1 PL 208588 B1 PL208588 B1 PL 208588B1 PL 373337 A PL373337 A PL 373337A PL 37333703 A PL37333703 A PL 37333703A PL 208588 B1 PL208588 B1 PL 208588B1
- Authority
- PL
- Poland
- Prior art keywords
- promoter
- pix
- adenovirus
- sequence
- sequences
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- 239000013598 vector Substances 0.000 title abstract description 134
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 207
- 238000004806 packaging method and process Methods 0.000 claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 28
- 230000001965 increasing effect Effects 0.000 claims abstract description 25
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 21
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 21
- 101150075174 E1B gene Proteins 0.000 claims description 78
- 230000014509 gene expression Effects 0.000 claims description 78
- 108091026890 Coding region Proteins 0.000 claims description 67
- 230000037430 deletion Effects 0.000 claims description 51
- 238000012217 deletion Methods 0.000 claims description 51
- 238000011144 upstream manufacturing Methods 0.000 claims description 50
- 230000000694 effects Effects 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 35
- 125000003729 nucleotide group Chemical group 0.000 claims description 35
- 108020004705 Codon Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 230000003612 virological effect Effects 0.000 claims description 27
- 108091081024 Start codon Proteins 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 16
- 230000001413 cellular effect Effects 0.000 claims description 8
- 241000714474 Rous sarcoma virus Species 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 241000701124 Human adenovirus 35 Species 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 24
- 108700026244 Open Reading Frames Proteins 0.000 abstract description 5
- 101150029662 E1 gene Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 170
- 241000700605 Viruses Species 0.000 description 163
- 239000012634 fragment Substances 0.000 description 99
- 108020004414 DNA Proteins 0.000 description 75
- 239000013612 plasmid Substances 0.000 description 70
- 241001135569 Human adenovirus 5 Species 0.000 description 54
- 101710114676 E1B 55 kDa protein Proteins 0.000 description 43
- 101150088856 pix gene Proteins 0.000 description 42
- 238000001890 transfection Methods 0.000 description 40
- 108700019146 Transgenes Proteins 0.000 description 37
- 230000000120 cytopathologic effect Effects 0.000 description 35
- 230000002068 genetic effect Effects 0.000 description 31
- 239000000499 gel Substances 0.000 description 28
- 239000000047 product Substances 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 24
- 108090000790 Enzymes Proteins 0.000 description 24
- 239000007858 starting material Substances 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000006166 lysate Substances 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 108060001084 Luciferase Proteins 0.000 description 13
- 239000005089 Luciferase Substances 0.000 description 13
- 108020005202 Viral DNA Proteins 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000002255 vaccination Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 241000598171 Human adenovirus sp. Species 0.000 description 10
- 108010019653 Pwo polymerase Proteins 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000003321 amplification Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000002845 virion Anatomy 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 201000005569 Gout Diseases 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 210000000234 capsid Anatomy 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 101710199711 Early E1A protein Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 description 3
- 108010045649 agarase Proteins 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000005100 tissue tropism Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 241001244729 Apalis Species 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001135572 Human adenovirus E4 Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 238000003120 Steady-Glo Luciferase Assay System Methods 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 241000990167 unclassified Simian adenoviruses Species 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101100189935 Arabidopsis thaliana PER55 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100282369 Caenorhabditis elegans gcc-2 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241001217856 Chimpanzee adenovirus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150059079 EBNA1 gene Proteins 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 101150034814 F gene Proteins 0.000 description 1
- 101150082239 G gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000701096 Human adenovirus 7 Species 0.000 description 1
- 241000701135 Human adenovirus D9 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000745906 Simian adenovirus 25 Species 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 241000701792 avian adenovirus Species 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- -1 deletion Chemical compound 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Lubricants (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL0200281 | 2002-04-25 | ||
| NL0200656 | 2002-10-15 | ||
| EP02102631 | 2002-11-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL373337A1 PL373337A1 (en) | 2005-08-22 |
| PL208588B1 true PL208588B1 (pl) | 2011-05-31 |
Family
ID=34068720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL373337A PL208588B1 (pl) | 2002-04-25 | 2003-04-24 | Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7285265B2 (https=) |
| EP (1) | EP1497440B1 (https=) |
| JP (1) | JP4495588B2 (https=) |
| KR (1) | KR101006594B1 (https=) |
| CN (1) | CN100374574C (https=) |
| AT (1) | ATE405663T1 (https=) |
| AU (1) | AU2003271738C1 (https=) |
| CA (1) | CA2478508C (https=) |
| DE (1) | DE60323080D1 (https=) |
| DK (1) | DK1497440T3 (https=) |
| ES (1) | ES2310247T3 (https=) |
| IL (1) | IL164802A0 (https=) |
| NO (1) | NO334299B1 (https=) |
| NZ (1) | NZ534865A (https=) |
| PL (1) | PL208588B1 (https=) |
| SI (1) | SI1497440T1 (https=) |
| WO (1) | WO2004001032A2 (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL160406A0 (en) | 1995-06-15 | 2004-07-25 | Crucell Holland Bv | A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products |
| US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| WO2003104467A1 (en) * | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| JP5213298B2 (ja) | 2002-05-27 | 2013-06-19 | ホルム，ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| US20040106194A1 (en) * | 2002-08-22 | 2004-06-03 | Bett Andrew J. | Methods for propagating adenovirus and virus produced thereby |
| US20050036989A1 (en) * | 2003-07-18 | 2005-02-17 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
| CA2546178A1 (en) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | New use of adenovirus and nucleic acids coding therefor |
| US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
| CN102220357B (zh) | 2004-11-16 | 2013-12-25 | 克鲁塞尔荷兰公司 | 包含重组病毒载体的多价疫苗 |
| US20090232800A1 (en) * | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
| SG158133A1 (en) | 2004-12-31 | 2010-01-29 | Sonne Holm | Method for reversing multiple resistance in animal cells |
| CA2602944C (en) | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| JP2008541730A (ja) * | 2005-05-23 | 2008-11-27 | ヴァクシン インコーポレイテッド | 高力価かつ複製コンピテントアデノウイルス不含である組換えアデノウイルスベクターの迅速な作成法 |
| EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| WO2008073578A2 (en) | 2006-12-08 | 2008-06-19 | Iowa State University Research Foundation, Inc. | Plant genes involved in nitrate uptake and metabolism |
| US10041049B2 (en) | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
| NZ602504A (en) | 2008-11-18 | 2014-01-31 | Beth Israel Hospital | Antiviral vaccines with improved cellular immunogenicity |
| RU2555346C2 (ru) | 2009-08-07 | 2015-07-10 | Трансген Са | Композиция для лечения инфекции вирусом гепатита в |
| US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
| BR112013004582A2 (pt) | 2010-09-27 | 2016-09-06 | Crucell Holland Bv | método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária |
| DK2655604T3 (en) | 2010-12-14 | 2018-08-06 | Us Gov Health & Human Services | ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES |
| EP3566714A1 (en) | 2011-11-28 | 2019-11-13 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| SI2825640T1 (sl) | 2012-03-12 | 2016-08-31 | Crucell Holland B.V. | Šarže rekombinantnega adenovirusa s spremenjenimi konci |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| JP5805908B2 (ja) | 2012-03-22 | 2015-11-10 | クルセル ホランド ベー ヴェー | Ｒｓｖに対するワクチン |
| EP2870236B1 (en) * | 2012-07-04 | 2018-01-10 | Sirion Biotech GmbH | Means and methods to increase adenovirus production |
| US10106781B2 (en) * | 2012-11-16 | 2018-10-23 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| KR102236497B1 (ko) | 2013-04-25 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드 |
| CA2960096A1 (en) | 2014-09-03 | 2016-03-10 | Bavarian Nordic A/S | Methods and compositions for enhancing immune responses |
| PT3188753T (pt) | 2014-09-03 | 2020-03-25 | Bavarian Nordic As | Métodos e composições para induzir imunidade protetora contra infeção por filovírus |
| CN106999571B (zh) | 2014-09-26 | 2020-10-02 | 贝斯以色列护理医疗中心有限公司 | 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物 |
| TWI710635B (zh) * | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
| JP6735288B2 (ja) | 2015-04-14 | 2020-08-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス |
| BE1023877B1 (fr) | 2015-05-21 | 2017-09-01 | Glaxosmithkline Biologicals Sa | Procédés et compositions pour l’induction d’une immunité protectrice contre une maladie et/ou une infection à filovirus |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| DK3584252T3 (da) | 2015-12-15 | 2021-11-15 | Janssen Vaccines & Prevention Bv | Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf |
| JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｒｓｖに対するワクチン |
| IL262108B2 (en) | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | Soluble pre-fusion rsv f proteins are stabilized |
| CN109154000B (zh) | 2016-05-12 | 2022-07-05 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
| CN109311946A (zh) | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
| MA45381A (fr) | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
| RU2745500C2 (ru) | 2016-06-20 | 2021-03-25 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
| WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| WO2018011198A1 (en) | 2016-07-15 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| EP3484507A1 (en) | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| WO2018075559A1 (en) | 2016-10-17 | 2018-04-26 | Beth Israel Deaconess Medical Center, Inc. | Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| US11034978B2 (en) | 2017-02-09 | 2021-06-15 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
| EP3606553A1 (en) | 2017-04-06 | 2020-02-12 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| KR20200015759A (ko) | 2017-06-15 | 2020-02-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법 |
| CN111163799A (zh) | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
| SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
| WO2019099970A1 (en) | 2017-11-20 | 2019-05-23 | Janssen Pharmaceuticals Inc. | Method of providing safe administration of adenoviral vectors encoding a zika virus antigen |
| US11773142B2 (en) | 2017-12-11 | 2023-10-03 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
| KR20200100745A (ko) | 2017-12-19 | 2020-08-26 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 |
| MX2020007077A (es) | 2018-01-04 | 2020-10-28 | Iconic Therapeutics Inc | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados. |
| EP3810277A1 (en) | 2018-07-20 | 2021-04-28 | Janssen Vaccines & Prevention B.V. | Recombinant adenoviral vector expressing zika antigen with improved productivity |
| MX2021005607A (es) | 2018-11-13 | 2021-06-30 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
| WO2020229577A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
| JP2022532742A (ja) | 2019-05-15 | 2022-07-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| CN110714027A (zh) * | 2019-10-28 | 2020-01-21 | 嘉铭(固安)生物科技有限公司 | 一种表达质粒、用于包装二代腺病毒的细胞株及其应用 |
| IL299571A (en) | 2020-07-08 | 2023-02-01 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| CN117821405B (zh) * | 2023-11-24 | 2024-11-26 | 广州医科大学 | 基因嵌合型人腺病毒及其构建方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| IL116816A (en) * | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| IL160406A0 (en) * | 1995-06-15 | 2004-07-25 | Crucell Holland Bv | A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products |
| US5922315A (en) | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
| WO1998050053A1 (en) | 1997-05-08 | 1998-11-12 | Genetic Therapy, Inc. | Gene transfer with adenoviruses having modified fiber proteins |
| US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| AU776067B2 (en) | 1999-03-04 | 2004-08-26 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
| ES2372823T3 (es) * | 1999-05-17 | 2012-01-26 | Crucell Holland B.V. | Adenovirus recombinante del serotipo ad11. |
| WO2003104467A1 (en) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
| US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6365394B1 (en) * | 1999-09-29 | 2002-04-02 | The Trustees Of The University Of Pennsylvania | Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| DE10045687B4 (de) * | 2000-09-15 | 2006-07-06 | MICROMUN Privates Institut für Mikrobiologische Forschung GmbH Biotechnikum Greifswald | Expressionskassetten und Adenovirusvektoren |
| CA2421864A1 (en) | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
| ATE449859T1 (de) | 2001-01-04 | 2009-12-15 | Goeran Wadell | Virusvektor zur gentherapie |
-
2003
- 2003-04-24 EP EP03753569A patent/EP1497440B1/en not_active Expired - Lifetime
- 2003-04-24 CA CA2478508A patent/CA2478508C/en not_active Expired - Fee Related
- 2003-04-24 JP JP2004514868A patent/JP4495588B2/ja not_active Expired - Lifetime
- 2003-04-24 AT AT03753569T patent/ATE405663T1/de active
- 2003-04-24 KR KR1020047016964A patent/KR101006594B1/ko not_active Expired - Fee Related
- 2003-04-24 CN CNB038092085A patent/CN100374574C/zh not_active Expired - Fee Related
- 2003-04-24 IL IL16480203A patent/IL164802A0/xx active IP Right Grant
- 2003-04-24 WO PCT/EP2003/050126 patent/WO2004001032A2/en not_active Ceased
- 2003-04-24 DE DE60323080T patent/DE60323080D1/de not_active Expired - Lifetime
- 2003-04-24 PL PL373337A patent/PL208588B1/pl unknown
- 2003-04-24 SI SI200331429T patent/SI1497440T1/sl unknown
- 2003-04-24 NZ NZ534865A patent/NZ534865A/en not_active IP Right Cessation
- 2003-04-24 US US10/512,602 patent/US7285265B2/en not_active Expired - Lifetime
- 2003-04-24 DK DK03753569T patent/DK1497440T3/da active
- 2003-04-24 AU AU2003271738A patent/AU2003271738C1/en not_active Ceased
- 2003-04-24 ES ES03753569T patent/ES2310247T3/es not_active Expired - Lifetime
-
2004
- 2004-11-24 NO NO20045131A patent/NO334299B1/no not_active IP Right Cessation
-
2007
- 2007-09-05 US US11/899,572 patent/US8052967B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2478508A1 (en) | 2003-12-31 |
| WO2004001032A2 (en) | 2003-12-31 |
| HK1069185A1 (en) | 2005-05-13 |
| CA2478508C (en) | 2013-07-02 |
| DK1497440T3 (da) | 2008-12-01 |
| NO334299B1 (no) | 2014-02-03 |
| CN100374574C (zh) | 2008-03-12 |
| EP1497440B1 (en) | 2008-08-20 |
| US20050163753A1 (en) | 2005-07-28 |
| US7285265B2 (en) | 2007-10-23 |
| CN1650021A (zh) | 2005-08-03 |
| JP2005523730A (ja) | 2005-08-11 |
| KR20040106365A (ko) | 2004-12-17 |
| NZ534865A (en) | 2008-07-31 |
| US20080206837A1 (en) | 2008-08-28 |
| ATE405663T1 (de) | 2008-09-15 |
| AU2003271738A1 (en) | 2004-01-06 |
| AU2003271738B2 (en) | 2007-10-11 |
| AU2003271738C1 (en) | 2008-04-17 |
| US8052967B2 (en) | 2011-11-08 |
| NO20045131L (no) | 2005-01-21 |
| DE60323080D1 (de) | 2008-10-02 |
| ES2310247T3 (es) | 2009-01-01 |
| EP1497440A2 (en) | 2005-01-19 |
| WO2004001032A3 (en) | 2004-04-01 |
| SI1497440T1 (sl) | 2009-02-28 |
| IL164802A0 (en) | 2005-12-18 |
| KR101006594B1 (ko) | 2011-01-07 |
| PL373337A1 (en) | 2005-08-22 |
| JP4495588B2 (ja) | 2010-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL208588B1 (pl) | Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa | |
| EP1497438B1 (en) | Means and methods for the production of adenovirus vectors | |
| AU763187B2 (en) | Generation of packaging system for human recombinant adenoviral vectors | |
| CZ182798A3 (cs) | Komplementární adenovirové vektorové systémy a buněčné linie | |
| US20050232900A1 (en) | Serotype of adenovirus and uses thereof | |
| Murakami et al. | An adenoviral vector expressing human adenovirus 5 and 3 fiber proteins for targeting heterogeneous cell populations | |
| US20050095231A1 (en) | Modified adenovirus containing a fiber replacement protein | |
| JP2002535986A (ja) | 遺伝子治療用の改良ヘルパーディペンデントベクター系 | |
| HK1069185B (en) | Stable adenoviral vectors and methods for propagation thereof | |
| HK1068371B (en) | Means and methods for the production of adenovirus vectors |